What is William Blair’s Estimate for Qiagen FY2024 Earnings?

Qiagen (NYSE:QGEN) – Investment analysts at William Blair lifted their FY2024 earnings per share (EPS) estimates for shares of Qiagen in a report released on Monday, November 11th. William Blair analyst A. Brackmann now forecasts that the company will earn $2.17 per share for the year, up from their previous forecast of $2.14. The consensus estimate for Qiagen’s current full-year earnings is $2.18 per share. William Blair also issued estimates for Qiagen’s Q2 2025 earnings at $0.57 EPS, Q3 2025 earnings at $0.58 EPS and FY2025 earnings at $2.26 EPS.

QGEN has been the topic of a number of other reports. Robert W. Baird lifted their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a research note on Thursday, October 17th. Finally, Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $50.88.

Qiagen Trading Down 1.9 %

Shares of QGEN stock opened at $43.23 on Wednesday. Qiagen has a twelve month low of $37.90 and a twelve month high of $47.44. The company has a current ratio of 2.17, a quick ratio of 1.46 and a debt-to-equity ratio of 0.39. The business’s 50 day moving average is $43.99 and its two-hundred day moving average is $43.78. The company has a market capitalization of $9.87 billion, a P/E ratio of 110.85, a price-to-earnings-growth ratio of 3.35 and a beta of 0.41.

Institutional Trading of Qiagen

Institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in shares of Qiagen by 806.5% during the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after acquiring an additional 500 shares during the period. Toronto Dominion Bank purchased a new position in Qiagen in the 2nd quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV raised its holdings in Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after purchasing an additional 243 shares during the last quarter. CWM LLC boosted its position in Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after purchasing an additional 269 shares in the last quarter. Finally, Headlands Technologies LLC grew its holdings in Qiagen by 396.6% in the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after purchasing an additional 2,189 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.